The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has ...
Dubbed the “King Kong” of weight loss jabs, Mounjaro, the brand name for tirzepatide, is a weekly injection licensed to treat type 2 diabetes on the NHS. Trials have shown some users can lose ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling ...
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
It was the insistent questioning of my four-year-old grandson that goaded me into it. “Why is your tummy so big” he asked ...